Alkeran

(melphalan)

ApprovedSmall molecule

Melphalan is a chemotherapy drug used to treat certain blood cancers, including multiple myeloma (cancer of blood cells in the bone marrow) and some types of lymphoma. It works by damaging cancer cell DNA to stop them from growing.[2] Alkeran is currently approved and in use across 62 indications[4].[1]

Alkeran is one of 828 small molecule programs targeting Neuroblastoma. It is currently in Approved.

Indications

598

Total Trials

Active Trials

827

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

NeuroblastomaRecruiting

Acute Myeloid LeukemiaNot yet recruiting

LymphomaTerminated

Non-Malignant DisordersRecruiting

Bone Marrow TransplantTerminated

TransplantationRecruiting

Anaplastic Large Cell LymphomaActive, not recruiting

Acute LeukemiaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Hodgkins LymphomaActive, not recruiting

NeuroblastomaPhase 3

Recruiting

Acute Myeloid LeukemiaPhase 3

Not yet recruiting

LymphomaPhase 3

Terminated

Non-Malignant DisordersPhase 2

Recruiting

Bone Marrow TransplantPhase 2

Terminated

TransplantationPhase 2

Recruiting

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

Acute LeukemiaPreclinical

Active, not recruiting

Metastatic MelanomaPreclinical

Active, not recruiting

Hodgkins LymphomaApproved

Active, not recruiting

Showing 10 of 62 indications

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Alkeran

AApotex Inc.

Approved

56 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Trial

NCT00871013

Phase 1/2Active, not recruiting

Multiple Myeloma

NCT01054196

Phase 3Recruiting

Conditioning

NCT06829472

N/AActive, not recruiting

Hematopoietic Stem Cell Transplant

NCT01652092

Phase 1/2Active, not recruiting

Hematological Malignancies

NCT00544466

Q4 2027

Phase 2Active, not recruiting

Remission

NCT00869232

Clinical

Trials by Indication[1]

Multiple Myeloma48 trials

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

Unknown status·MMedical College of Wisconsin·Phase 2·NCT00003163·10 enrolled

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003146

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

Completed·UUniversity of Illinois at Chicago·Phase 1·NCT02043847·12 enrolled

Show 45 more trials

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 1/2·NCT01335685·61 enrolled

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Completed·FFondazione EMN Italy Onlus·Phase 3·NCT01091831·389 enrolled

Rituximab in Treating Patients With Multiple Myeloma

Completed·TThe Cleveland Clinic·Phase 2·NCT00003554

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003401

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02195479·706 enrolled

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02728102·203 enrolled

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00003954·40 enrolled

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Completed·FFondazione EMN Italy Onlus·Phase 3·NCT00551928·402 enrolled

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Completed·MMayo Clinic·Phase 1/2·NCT00602706·76 enrolled

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Terminated·HHackensack Meridian Health·Phase 2·NCT01453088·63 enrolled

MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning

Completed·PPETHEMA Foundation·Phase 2·NCT00564200·30 enrolled

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Unknown status·SSwedish Medical Center·Phase 2·NCT03570983·100 enrolled

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002653·1,000 enrolled

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Completed·—·Phase 1/2·NCT00112827·54 enrolled

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02474563·171 enrolled

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Withdrawn·MMayo Clinic·Phase 1/2·NCT00995059

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT00566098·26 enrolled

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00313625·20 enrolled

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Completed·MMayo Clinic·Phase 1·NCT00477815·30 enrolled

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1/2·NCT00334932·32 enrolled

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006244·36 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003399

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Unknown status·RRiverside Haematology Group·Phase 3·NCT00003603·660 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00014508

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Active, not recruiting·WWeill Medical College of Cornell University·Phase 1/2·NCT01054196·52 enrolled

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002678·595 enrolled

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Unknown status·EErasme University Hospital·Phase 2·NCT00526734·100 enrolled

A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT00985959·101 enrolled

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00054353·16 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Unknown status·—·Phase 2·NCT00004903

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Completed·PPETHEMA Foundation·Phase 2·NCT01237249·250 enrolled

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

Completed·MMayo Clinic·Phase 2·NCT00002630·50 enrolled

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00217438·130 enrolled

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Terminated·UUniversity of Colorado, Denver·Phase 1/2·NCT02353572·3 enrolled

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Withdrawn·OOncotherapeutics·Phase 2·NCT00085345

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00948922·124 enrolled

THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)

Completed·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 2·NCT01341262·378 enrolled

Stem Cell Transplantation for Patients With Multiple Myeloma

Completed·UUniversity of Chicago·Phase 1·NCT01526096·30 enrolled

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

Completed·UUniversity Hospital, Toulouse·Phase 3·NCT02197221·300 enrolled

ASCT With Nivolumab in Patients With Multiple Myeloma

Active, not recruiting·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT03292263·30 enrolled

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00325416·177 enrolled

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00911859·118 enrolled

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

Completed·HHackensack Meridian Health·Phase 1/2·NCT00784823·32 enrolled

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

Completed·—·Phase 4·NCT01731886·60 enrolled

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Active, not recruiting·UUniversity of Turin, Italy·Phase 4·NCT03829371·450 enrolled

Lymphoma18 trials

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00012051·340 enrolled

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01840566·17 enrolled

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00992446·27 enrolled

Show 15 more trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002982

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00080886·68 enrolled

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00669812·60 enrolled

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00908180·47 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00005589·460 enrolled

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00244946·15 enrolled

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Terminated·AAHS Cancer Control Alberta·Phase 1/2·NCT02295722·100 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Completed·SSwiss Cancer Institute·Phase 3·NCT00003215·400 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Completed·—·N/A·NCT01702961·75 enrolled

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00907036·49 enrolled

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027937

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Withdrawn·FFred Hutchinson Cancer Center·N/A·NCT01769911

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Completed·SSwiss Cancer Institute·Phase 1·NCT00392691·20 enrolled

Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025064·260 enrolled

Neuroblastoma12 trials

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Completed·—·Phase 3·NCT00002802·500 enrolled

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 3·NCT00410631·642 enrolled

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Unknown status·UUniversity of Leicester·Phase 3·NCT00030719·175 enrolled

Show 9 more trials

Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00024193

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

Completed·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00365755

Chemotherapy in Treating Children With Neuroblastoma

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT00002730

Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

Completed·SSamsung Medical Center·Phase 2·NCT00793845·40 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00017368·42 enrolled

Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Completed·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 2·NCT00017225

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·N/A·NCT00526318·360 enrolled

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00417053

N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT00005978

Stem Cell Transplant8 trials

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Completed·WWeill Medical College of Cornell University·Phase 2·NCT02497404·40 enrolled

Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00248430·20 enrolled

Show 5 more trials

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Terminated·UUniversity of California, San Francisco·N/A·NCT00301860·8 enrolled

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recruiting·UUniversity of Chicago·Phase 1·NCT02333162·30 enrolled

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Active, not recruiting·DDiane George·Phase 1/2·NCT02061800·14 enrolled

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027560·51 enrolled

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00423514·38 enrolled

Colorectal Cancer5 trials

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 3·NCT00020501

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001576·28 enrolled

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00089401·8 enrolled

Show 2 more trials

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00019760

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00103298

74 more indications

Transplantation5 trials

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Completed·SStanford University·Phase 2·NCT00899847·9 enrolled

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038831·47 enrolled

Show 2 more trials

Completed·MMassachusetts General Hospital·Phase 2·NCT00133367·32 enrolled

Pilot Study of Unrelated Cord Blood Transplantation

Terminated·KKing's College Hospital NHS Trust·Phase 2·NCT00916045·40 enrolled

Stem Cell Transplantation4 trials

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00043979·60 enrolled

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002599·750 enrolled

Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy

Completed·AAustrian Forum Against Cancer·Phase 3·NCT00205764·212 enrolled

Show 1 more trial

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003396·42 enrolled

Amyloidosis4 trials

Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis

Completed·NNantes University Hospital·Phase 1/2·NCT00621400·27 enrolled

Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis

Completed·UUniversity Hospital, Limoges·Phase 3·NCT00344526·100 enrolled

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

Completed·—·Phase 2·NCT00075621·62 enrolled

Show 1 more trial

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Terminated· Takeda logo

Takeda·Phase 3·NCT01659658·177 enrolled

Bone Marrow Transplantation4 trials

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1/2·NCT00003086·12 enrolled

High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Unknown status·LLymphoma Trials Office·Phase 3·NCT00003578·500 enrolled

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00014469

Show 1 more trial

Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Unknown status·SScotland and Newcastle Lymphoma Group·Phase 3·NCT00003815

Chronic Lymphocytic Leukemia3 trials

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00275015·169 enrolled

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00276809·30 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003402·35 enrolled

Melanoma3 trials

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001296·122 enrolled

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003789·216 enrolled

Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment

Unknown status·IInternational Group of Endovascular Oncology··NCT01920516·40 enrolled

Hematopoietic Stem Cell Transplant3 trials

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT02614560·14 enrolled

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01652092·57 enrolled

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed·UUniversity of California, San Francisco··NCT03609827·25 enrolled

Hematologic Cancer3 trials

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Completed·—·Phase 2·NCT00003335·44 enrolled

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003661·3 enrolled

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

Withdrawn·—·Phase 1·NCT00003435

Conditioning3 trials

Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT06829472·120 enrolled

Reduced Intensity Conditioning Transplant Using Haploidentical Donors

Completed·NNorthside Hospital, Inc.·Phase 2·NCT02581007·25 enrolled

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03385096·122 enrolled

Breast Cancer3 trials

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Terminated·UUniversity of California, San Diego·Phase 2·NCT00074269·5 enrolled

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

Completed·YYale University·Phase 2·NCT00002680·40 enrolled

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003199·50 enrolled

Hematologic Malignancies2 trials

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04191187·34 enrolled

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02199041·24 enrolled

Liver Cancer2 trials

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00019786·67 enrolled

Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00030082

Leukemia2 trials

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

Completed·UUniversity of Miami·N/A·NCT02007863·2 enrolled

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00055653

Acute Leukemia2 trials

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Unknown status·DDutch Childhood Oncology Group·N/A·NCT00550992·445 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008190

Infusion2 trials

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

Terminated·OOncopeptides AB·Phase 2·NCT04412707·27 enrolled

A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

Completed·AAdherex Technologies, Inc.·Phase 1/2·NCT00421811·56 enrolled

Stage IV Ovarian Epithelial Cancer2 trials

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003413·32 enrolled

Retinoblastoma2 trials

Conservative Treatments of Retinoblastoma

Active, not recruiting·IInstitut Curie·Phase 2·NCT02866136·133 enrolled

Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma

Recruiting·EEye & ENT Hospital of Fudan University·N/A·NCT04903678·18 enrolled

Soft Tissue Sarcoma2 trials

Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00019968

Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004250·35 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation2 trials

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00429026·40 enrolled

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Terminated·MMontefiore Medical Center·Phase 1·NCT02653196·1 enrolled

Dexamethasone2 trials

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

Completed·UUniversity of Arkansas·Phase 3·NCT00083915·97 enrolled

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

Completed· Takeda logo

Takeda·Phase 3·NCT00507416·502 enrolled

Trial1 trial

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00871013·160 enrolled

TED1 trial

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03579875·48 enrolled

Treatment1 trial

MUK Nine b: OPTIMUM Treatment Protocol

Active, not recruiting·UUniversity of Leeds·Phase 2·NCT03188172·95 enrolled

Kidney Transplant1 trial

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Recruiting·AAlice Bertaina·Phase 1/2·NCT05508009·12 enrolled

Suicide1 trial

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01875237·3 enrolled

Hematologic Malignancy1 trial

Terminated·—·Phase 2·NCT01500161·1 enrolled

Lenalidomide1 trial

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Completed·PPETHEMA Foundation·Phase 3·NCT01916252·460 enrolled

Primitive Neuroectodermal Tumor1 trial

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003081·16 enrolled

Autologous Hematopoietic Stem Cell Transplantation1 trial

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT01690143·45 enrolled

Chronic Myelogenous Leukemia1 trial

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Primary Systemic Amyloidosis1 trial

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089167

Ewing sarcoma1 trial

A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma

Withdrawn·UUniversity of Louisville·Phase 1·NCT01969942

Myelodysplastic Syndromes1 trial

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·TThe University of New South Wales·Phase 2/3·NCT00454480·2,000 enrolled

High Risk1 trial

HSCT for High Risk Inherited Inborn Errors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00383448·38 enrolled

Toxicity1 trial

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed·UUniversity of Louisville·Phase 1·NCT02472392·10 enrolled

Exercise1 trial

Effects of Exercise in Combination With Epoetin Alfa

Completed·UUniversity of Arkansas·N/A·NCT00577096·120 enrolled

Metabolic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003662·90 enrolled

Arsenic Trioxide1 trial

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00661544·48 enrolled

Mesenchymal Stem Cells1 trial

Cord Blood Expansion on Mesenchymal Stem Cells

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00498316·98 enrolled

Central Nervous System Lymphoma1 trial

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003632·30 enrolled

Genetic Disorder1 trial

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008307·52 enrolled

Acute Lymphoblastic Leukaemia1 trial

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT03821610·242 enrolled

Refractory Solid Tumors1 trial

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Completed·MMilton S. Hershey Medical Center·Phase 1·NCT00112645·10 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615144·1 enrolled

Mantle Cell Lymphoma1 trial

Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Unknown status·GGerman Low Grade Lymphoma Study Group·Phase 3·NCT00016887

Relapsed or Refractory Hematologic Malignancies1 trial

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02259348·12 enrolled

Recurrent or Refractory Solid Tumors1 trial

Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003899

Malignant Solid Tumors1 trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00436761·20 enrolled

Relapsed or Refractory1 trial

Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025103·75 enrolled

Allogeneic Stem Cell Transplantation1 trial

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01518153·16 enrolled

Myelofibrosis1 trial

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Completed·—·Phase 1·NCT02917096·18 enrolled

Locally Advanced1 trial

Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00181025·33 enrolled

Solid Tumors1 trial

MT2004-30: Tomotherapy for Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00623077·23 enrolled

Donor1 trial

URMC Related Haplo-identical Donor BMT

Completed·UUniversity of Rochester·Phase 1·NCT02660281·74 enrolled

Pilot Study1 trial

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Completed·—·Phase 2·NCT00003336·6 enrolled

Tic Disorder1 trial

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00176865·19 enrolled

Memory1 trial

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02790515·170 enrolled

Remission1 trial

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00869232·90 enrolled

Lymphoid Malignancies1 trial

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00439556·40 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed·WWashington University School of Medicine·Phase 1·NCT03072771·14 enrolled

Relapsed/Refractory1 trial

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Unknown status·SSwedish Medical Center·Phase 2·NCT03736616·47 enrolled

Immunodeficiency1 trial

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Active, not recruiting·AAIDS Malignancy Consortium·Phase 1/2·NCT02797470·11 enrolled

AL amyloidosis1 trial

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01807286·3 enrolled

Advanced Hematologic Malignancies1 trial

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Completed·UUniversity of Chicago·Phase 1/2·NCT00943592·82 enrolled

Myeloma1 trial

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00469209·60 enrolled

Myelodysplastic Syndrome1 trial

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002989·207 enrolled

Graft Versus Host Disease1 trial

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Completed·—·Phase 2·NCT00589563·32 enrolled

Hemoglobinopathies1 trial

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

Completed·NNorthwell Health·Phase 1/2·NCT02435901·29 enrolled

Brain Tumors1 trial

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00303849·33 enrolled

Recruiting·—·Phase 1·NCT04678401·30 enrolled

Acute Myeloid Leukemia1 trial

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 3·NCT00002945·61 enrolled

Hematological Malignancies1 trial

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

Active, not recruiting·—·Phase 1/2·NCT00544466·75 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ALKERAN

NDA NDA014691

Nov 18, 1992

ALKERAN

NDA NDA020207

Mar 10, 2016

EVOMELA

NDA NDA207155

Aug 14, 2023

HEPZATO

NDA NDA201848

Aug 18, 2023

IVRA

NDA NDA217110

Sources

References

[1]
ClinicalTrials.gov — 598 trial records for melphalan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Alkeran drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — melphalan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for melphalan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217110). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Alkeran. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Apotex Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AApotex Inc.

Patent Landscape[6]

Patent Cliff

May 28, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11020363May 28, 2030

10864183May 28, 2030

10940128Jun 14, 2030

10369264Nov 7, 2032

10098997Nov 7, 2032

10 more patents

11633528Nov 7, 2032

11241522Nov 7, 2032

10569004Nov 7, 2032

11083831Dec 30, 2032

11833286Dec 30, 2032

10195334Jan 16, 2033

10040872Jan 30, 2034

9314561Feb 7, 2034

9707331Sep 17, 2034

10537520Jun 29, 2036